News and Announcements
4Dx to Present at Lung Imaging Workshop in the U.S.
- Published February 20, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
4Dx Limited is a medical technology start-up based in Melbourne, Australia, established to commercialise four-dimensional lung imaging technology.
KEY TAKEAWAYS:
- Dr Andreas Fouras, founder and CEO of medical technology company 4Dx Limited, will present at the World Lung Imaging Workshop at the University of Pennsylvania.
“The software developed by 4Dx provides richer information, allowing for earlier detection of respiratory related disease. It captures images that effectively visualise and quantify motion of airflow at high resolution within the breathing lungs.
The company has a range of formal engagements with some leading institutions across the United States and is moving towards a commercial product in the US by 2018.”
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
